|
1
|
Basu Mallick A and Chawla SP: Giant cell
tumor of bone: An update. Curr Oncol Rep. 23:512021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Errani C, Tsukamoto S, Ciani G and Donati
DM: Present day controversies and consensus in curettage for giant
cell tumor of bone. J Clin Orthop Trauma. 10:1015–1020. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tsukamoto S, Mavrogenis AF, Kido A and
Errani C: Current concepts in the treatment of giant cell tumors of
bone. Cancers (Basel). 13:36472021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gupta A, Durocher-Allen L, Popovic S,
Tozer R, Yao X and Ghert M: The role of denosumab for surgical
outcomes in patients with giant cell tumour of bone: A systematic
review. Curr Oncol. 28:1302–1313. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li H, Gao J, Gao Y, Lin N, Zheng M and Ye
Z: Denosumab in giant cell tumor of bone: Current status and
pitfalls. Front Oncol. 10:5806052020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thomas D, Henshaw R, Skubitz K, Chawla S,
Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, et al:
Denosumab in patients with giant-cell tumour of bone: An
open-label, phase 2 study. Lancet Oncol. 11:275–280. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chawla S, Blay JY, Rutkowski P, Le Cesne
A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger
L, et al: Denosumab in patients with giant-cell tumour of bone: A
multicentre, open-label, phase 2 study. Lancet Oncol. 20:1719–1729.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Palmerini E, Picci P, Reichardt P and
Downey G: Malignancy in giant cell tumor of bone: A review of the
literature. Technol Cancer Res Treat. 18:15330338198400002019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murphy WR and Ackerman LV: Benign and
malignant giant-cell tumors of bone; a clinical-pathological
evaluation of thirty-one cases. Cancer. 9:317–339. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mnaymneh WA, Dudley HR and Mnaymneh LG:
Giant-cell tumor of bone: An analysis and follow-up study of the
forty-one cases observed at the Massachusetts general hospital
between 1925 and 1960. J Bone Joint Surg Am. 46:63–75. 1964.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dahlin DC, Cupps RE and Johnson EW:
Giant-cell tumor: A study of 195 cases. Cancer. 25:1061–1070. 1970.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sundaram M, Martin AS and Tayob AA: Case
report 182: Osteosarcoma arising in giant cell tumor of tibia.
Skeletal Radiol. 7:282–285. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rock MG, Sim FH, Unni KK, Witrak GA,
Frassica FJ, Schray MF, Beabout JW and Dahlin DC: Secondary
malignant giant-cell tumor of bone. Clinicopathological assessment
of nineteen patients. J Bone Joint Surg Am. 68:1073–1079. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gitelis S, Wang JW, Quast M, Schajowicz F
and Templeton A: Recurrence of a giant-cell tumor with malignant
transformation to a fibrosarcoma twenty-five years after primary
treatment. A case report. J Bone Joint Surg Am. 71:757–761. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hefti FL, Gächter A, Remagen W and
Nidecker A: Recurrent giant-cell tumor with metaplasia and
malignant change, not associated with radiotherapy. A case report.
J Bone Joint Surg Am. 74:930–934. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Anract P, De Pinieux G, Cottias P,
Pouillart P, Forest M and Tomeno B: Malignant giant-cell tumours of
bone. Clinico-pathological types and prognosis: A review of 29
cases. Int Orthop. 22:19–26. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mori Y, Tsuchiya H, Karita M, Nonomura A,
Nojima T and Tomita K: Malignant transformation of a giant cell
tumor 25 years after initial treatment. Clin Orthop Relat Res.
381:185–191. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oda Y, Sakamoto A, Saito T, Matsuda S,
Tanaka K, Iwamoto Y and Tsuneyoshi M: Secondary malignant
giant-cell tumour of bone: Molecular abnormalities of p53 and H-ras
gene correlated with malignant transformation. Histopathology.
39:629–637. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marui T, Yamamoto T, Yoshihara H, Kurosaka
M, Mizuno K and Akamatsu T: De novo malignant transformation of
giant cell tumor of bone. Skeletal Radiol. 30:104–108. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bertoni F, Bacchini P and Staals EL:
Malignancy in giant cell tumor of bone. Cancer. 97:2520–2529. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hashimoto K, Hatori M, Hosaka M, Watanabe
M, Hasegawa T and Kokubun S: Osteosarcoma arising from giant cell
tumor of bone ten years after primary surgery: A case report and
review of the literature. Tohoku J Exp Med. 208:157–162. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Machinami R, Nishida K, Ishida T,
Matsumoto S, Kuroda K, Kobayashi M, Takeuchi K and Ishikawa Y:
Carcinosarcomatous malignancy, osteosarcoma and squamous cell
carcinoma, in giant cell tumor of the right distal femur. Pathol
Res Pract. 204:583–588. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miller IJ, Blank A, Yin SM, McNickle A,
Gray R and Gitelis S: A case of recurrent giant cell tumor of bone
with malignant transformation and benign pulmonary metastases.
Diagn Pathol. 5:622010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Picci P, Sieberova G, Alberghini M,
Balladelli A, Vanel D, Hogendoorn PC and Mercuri M: Late sarcoma
development after curettage and bone grafting of benign bone
tumors. Eur J Radiol. 77:19–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kadowaki M, Yamamoto S and Uchio Y: Late
malignant transformation of giant cell tumor of bone 41 years after
primary surgery. Orthopedics. 35:e1566–e1570. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Muramatsu K, Ihara K, Miyoshi T, Kawakami
Y, Nakashima D and Taguchi T: Late development of malignant fibrous
histiocytoma at the site of a giant cell tumour 38 years after
initial surgery. Acta Orthop Belg. 78:279–284. 2012.PubMed/NCBI
|
|
27
|
Li J, Zhu Y and Wei Y: Fibrosarcoma
development 15 years after curettage and bone grafting of giant
cell tumor of bone. Orthopedics. 37:e512–e516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yin H, Cheng M, Li B, Li B, Wang P, Meng
T, Wang J, Zhou W, Yan W and Xiao J: Treatment and outcome of
malignant giant cell tumor in the spine. J Neurooncol. 124:275–281.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Takesako H, Osaka E, Yoshida Y, Sugitani M
and Tokuhashi Y: Secondary malignant giant cell tumor of bone due
to malignant transformation 40 years after surgery without
radiation therapy, presenting as fever of unknown origin: A case
report. J Med Case Rep. 10:472016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu W, Chan CM, Gong L, Bui MM, Han G,
Letson GD, Yang Y and Niu X: Malignancy in giant cell tumor of bone
in the extremities. J Bone Oncol. 26:1003342020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tsukamoto S, Righi A, Mavrogenis AF,
Akahane M, Honoki K, Tanaka Y, Donati DM and Errani C: Late local
recurrence of bone giant cell tumors associated with an increased
risk for malignant transformation. Cancers (Basel). 13:36442021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alaqaili SI, Abduljabbar AM, Altaho AJ,
Khan AA and Alherabi JA: Malignant sarcomatous transformation of
benign giant cell tumor of bone after treatment with denosumab
therapy: A literature review of reported cases. Cureus.
10:e37922018.PubMed/NCBI
|
|
33
|
Rutkowski P, Ferrari S, Grimer RJ, Stalley
PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A,
et al: Surgical downstaging in an open-label phase II trial of
denosumab in patients with giant cell tumor of bone. Ann Surg
Oncol. 22:2860–2868. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Broehm CJ, Garbrecht EL, Wood J and
Bocklage T: Two cases of sarcoma arising in giant cell tumor of
bone treated with denosumab. Case Rep Med. 2015:7671982015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Aponte-Tinao LA, Piuzzi NS, Roitman P and
Farfalli GL: A high-grade sarcoma arising in a patient with
recurrent benign giant cell tumor of the proximal tibia while
receiving treatment with denosumab. Clin Orthop Relat Res.
473:3050–3055. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Park A, Cipriano CA, Hill K, Kyriakos M
and McDonald DJ: Malignant transformation of a giant cell tumor of
bone treated with denosumab: A case report. JBJS Case Connect.
6:e782016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tsukamoto S, Righi A, Vanel D, Honoki K,
Donati DM and Errani C: Development of high-grade osteosarcoma in a
patient with recurrent giant cell tumor of the ischium while
receiving treatment with denosumab. Jpn J Clin Oncol. 47:1090–1096.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hasenfratz M, Mellert K, Marienfeld R, von
Baer A, Schultheiss M, Roitman PD, Aponte-Tinao LA, Lehner B,
Möller P, Mechtersheimer G and Barth TFE: Profiling of three
H3F3A-mutated and denosumab-treated giant cell tumors of bone
points to diverging pathways during progression and malignant
transformation. Sci Rep. 11:57092021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yung D, Asano N, Hirozane T, Yamaguchi S,
Mori T, Susa M, Okita H, Morioka H, Horiuchi K and Nakayama R:
Malignant transformation of metastatic giant cell tumor of bone in
a patient undergoing denosumab treatment: A case report. J Orthop
Sci. S0949-2658(21)00222-0. 2021.(Epub ahead of print). View Article : Google Scholar
|
|
40
|
Palmerini E, Seeger LL, Gambarotti M,
Righi A, Reichardt P, Bukata S, Blay JY, Dai T, Jandial D and Picci
P: Malignancy in giant cell tumor of bone: Analysis of an
open-label phase 2 study of denosumab. BMC Cancer. 21:892021.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gong L, Liu W, Sun X, Sajdik C, Tian X,
Niu X and Huang X: Histological and clinical characteristics of
malignant giant cell tumor of bone. Virchows Arch. 460:327–334.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Okubo T, Saito T, Mitomi H, Takagi T,
Torigoe T, Suehara Y, Kaneko K and Yao T: p53 mutations may be
involved in malignant transformation of giant cell tumor of bone
through interaction with GPX1. Virchows Archiv. 463:67–77. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bieg-Bourne CC, Millis SZ, Piccioni DE,
Fanta PT, Goldberg ME, Chmielecki J, Parker BA and Kurzrock R:
Next-Generation sequencing in the clinical setting clarifies
patient characteristics and potential actionability. Cancer Res.
77:6313–6320. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li LT, Jiang G, Chen Q and Zheng JN: Ki67
is a promising molecular target in the diagnosis of cancer
(review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ishihara S, Yamamoto H, Iwasaki T, Toda Y,
Yamamoto T, Yoshimoto M, Ito Y, Susuki Y, Kawaguchi K, Kinoshita I,
et al: Histological and immunohistochemical features and genetic
alterations in the malignant progression of giant cell tumor of
bone: A possible association with TP53 mutation and loss of H3K27
trimethylation. Mod Pathol. 35:640–648. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Movahedinia S, Shooshtarizadeh T and
Mostafavi H: Secondary malignant transformation of giant cell tumor
of bone: Is it a fate? Iran J Pathol. 14:165–174. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Miranda Alcalde B, Villa Alcázar M,
Martínez Romera I and López Ibor B: The importance of Li-Fraumeni
syndrome, a hereditary cancer predisposition disorder. Arch Argent
Pediatr. 119:e11–e17. 2021.Mantovani F, Collavin L and Del Sal G:
Mutant p53 as a guardian of the cancer cell. Cell Death Differ 26,
199–212, 2019. PubMed/NCBI
|
|
48
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
González-Gil C, Ribera J, Ribera JM and
Genescà E: The Yin and Yang-like clinical implications of the
CDKN2A/ARF/CDKN2B gene cluster in acute lymphoblastic leukemia.
Genes (Basel). 12:792021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gong L, Bui MM, Zhang W, Sun X, Zhang M
and Yi D: H3F3A G34 mutation DNA sequencing and G34W
immunohistochemistry analysis in 366 cases of giant cell tumors of
bone and other bone tumors. Histol Histopathol. 36:61–68.
2021.PubMed/NCBI
|
|
51
|
Behjati S, Tarpey PS, Presneau N, Scheipl
S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, et
al: Distinct H3F3A and H3F3B driver mutations define
chondroblastoma and giant cell tumor of bone. Nat Genet.
45:1479–1482. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yoshida KI, Nakano Y, Honda-Kitahara M,
Wakai S, Motoi T, Ogura K, Sano N, Shibata T, Okuma T, Iwata S, et
al: Absence of H3F3A mutation in a subset of malignant giant cell
tumor of bone. Mod Pathol. 32:1751–1761. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Imai R, Kamada T and Araki N; Working
Group for Bone, . Soft Tissue Sarcomas: Carbon ion radiation
therapy for unresectable sacral chordoma: An analysis of 188 cases.
Int J Radiat Oncol Biol Phys. 95:322–327. 2016. View Article : Google Scholar : PubMed/NCBI
|
